Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC) Meeting Abstract


Authors: Traina, T. A.; Miller, K.; Yardley, D. A.; O'Shaughnessy, J.; Cortes, J.; Awada, A.; Kelly, C. M.; Trudeau, M. E.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Nanda, R.; Ademuyiwa, F. O.; Chan, S.; Steinberg, J. L.; Blaney, M. E.; Tudor, I. C.; Uppal, H.; Peterson, A. C.; Hudis, C. A.
Abstract Title: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC)
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036900035
PROVIDER: wos
Notes: Meeting Abstract: 1003 -- Source: Wos